8. Cacabelos R, Alvarez XA, Franco MA. et al. Effect  of CDP choline on cognition and inmune function in Alzheimer Diseases and multi infarct dementia. Ann NY Acad. Sci.   695: 321-323, 1993.

     9. Rogers S. Clinical profile of donepezil (E2020). Neurobiol Aging 17(4S): S46, 1996.

     10. Anand R, Gharabawi G. Efficacy and safety results of the early phase studies with Exelon (ENA 713) in Alzheimer Diseases: an overview. J Grug Dev Clin Pract. 8: 1-14, 1996.

     11. Becker RE, Colliver JA, Markwell SJ. et al. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimers Disease. Alzheimers. Dis. Assoc. Disord. 10: 124-131, 1996.

     12. Schneider IS, Pollock VE, Zemansky MF. et al. A pilot studyof low dose l-deprenyl in Alzheimers disease. J. Geriatr. Psychiatry Neurol. 4: 143-148, 1991.

     13. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of seligiline, alpha-tocopherol, or both as treatment for Alzheimers disease. N Engl J Med  333: 1216-1222, 1997.
Autor: FUNDACION SANTAFE DE BOGOTA
 
<< Pgina Anterior           Pgina Siguiente >> 

[Pgina 1]    [Pgina 2]    [Pgina 3]    [Pgina 4]    [Pgina 5]    [Pgina 6]    
[Pgina 7]    [Pgina 8]